Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pedneo.2019.03.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Pharmacokinetic Changes in Cystic Fibrosis Patients Population: Narrative Review.
Medicines (Basel)
December 2024
Pharmacy School, West Coast University, Los Angeles, CA 90004, USA.
Cystic fibrosis (CF) is a rare genetic disorder commonly affecting multiple organs such as the lungs, pancreas, liver, kidney, and intestine. Our search focuses on the pathophysiological changes that affect the drugs' absorption, distribution, metabolism, and excretion (ADME). This review aims to identify the ADME data that compares the pharmacokinetics (PK) of different drugs in CF and healthy subjects.
View Article and Find Full Text PDFPerspectives in MicroRNA Therapeutics for Cystic Fibrosis.
Noncoding RNA
January 2025
Department of Life Sciences and Biotechnology, Section of Biochemistry and Molecular Biology, University of Ferrara, 44121 Ferrara, Italy.
The discovery of the involvement of microRNAs (miRNAs) in cystic fibrosis (CF) has generated increasing interest in the past years, due to their possible employment as a novel class of drugs to be studied in pre-clinical settings of therapeutic protocols for cystic fibrosis. In this narrative review article, consider and comparatively evaluate published laboratory information of possible interest for the development of miRNA-based therapeutic protocols for cystic fibrosis. We consider miRNAs involved in the upregulation of CFTR, miRNAs involved in the inhibition of inflammation and, finally, miRNAs exhibiting antibacterial activity.
View Article and Find Full Text PDFAntimicrobial peptide glatiramer acetate targets Pseudomonas aeruginosa lipopolysaccharides to breach membranes without altering lipopolysaccharide modification.
NPJ Antimicrob Resist
February 2024
National Heart and Lung Institute, Imperial College London, London, UK.
Antimicrobial peptides (AMPs) are key components of innate immunity across all domains of life. Natural and synthetic AMPs are receiving renewed attention in efforts to combat the antimicrobial resistance (AMR) crisis and the loss of antibiotic efficacy. The gram-negative pathogen Pseudomonas aeruginosa is one of the most concerning infecting bacteria in AMR, particularly in people with cystic fibrosis (CF) where respiratory infections are difficult to eradicate and associated with increased morbidity and mortality.
View Article and Find Full Text PDFPolymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery.
NPJ Antimicrob Resist
November 2024
College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK.
Polymicrobial communities inhabit the cystic fibrosis (CF) airway, whereby microbial interactions can occur. One prominent CF pathogen is Mycobacterium abscessus, whose treatment is largely unsuccessful. This creates a need to discover novel antimicrobial agents to treat M.
View Article and Find Full Text PDFCystic fibrosis sputum media induces an overall loss of antibiotic susceptibility in Mycobacterium abscessus.
NPJ Antimicrob Resist
November 2024
College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK.
Mycobacterium abscessus complex (MABSC) comprises a group of environmental microorganisms, which are a concerning cause of opportunistic respiratory infections in patients with cystic fibrosis or bronchiectasis. Only 45.6% of MABSC treatments are successful, and therefore this is a need to discover new antimicrobials that can treat these pathogens.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!